ZYDUSLIFE

announced positive results from its EPICS-III trial evaluating Saroglitazar Magnesium in patients with Primary Biliary Cholangitis, a rare autoimmune liver disease. The trial met its primary endpoint with 48.5% of patients showing a meaningful biochemical response and complete normalization of alkaline phosphatase. USFDA approval is targeted for 2026.